Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma

被引:0
|
作者
dos Santos, Margarida Varela [1 ,5 ]
Holth, Arild [1 ]
Lindemann, Kristina [2 ,3 ]
Staff, Anne Cathrine [2 ,4 ]
Davidson, Ben [1 ,2 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, N-0310 Oslo, Norway
[4] Oslo Univ Hosp, Ulleval Hosp, Dept Obstet & Gynecol, N-0450 Oslo, Norway
[5] Ctr Hospitalar Univ Lisboa Cent EPE, Serv Anat Patol, Rua Jose Antonio Serrano, P-1150199 Lisbon, Portugal
关键词
L1CAM; Immunohistochemistry; High-grade serous carcinoma; Effusion; Chemoresistance; Survival; OVARIAN-CANCER; L1; PROGRESSION; DIAGNOSIS; CELLS; CD171;
D O I
10.1016/j.ygyno.2023.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To analyze the expression and prognostic role of L1CAM in tubo-ovarian high-grade serous carci-noma (HGSC).Methods. L1CAM protein expression by immunohistochemistry was analyzed in 644 HGSC (413 effusions, 231 surgical specimens). Expression was analyzed for association with clinicopathologic parameters and survival.Results. L1CAM protein expression was found in 401/413 (97%) effusions and 209/231 (90%) surgical speci-mens, with significantly higher staining extent in effusions (p < 0.001). L1CAM protein expression in effusions was unrelated to clinicopathologic parameters (p > 0.05). In surgical specimens, higher L1CAM expression was significantly related to primary (intrinsic) chemoresistance (p = 0.017). High (>25%) L1CAM expression in HGSC effusions (p = 0.02), older patient age (p = 0.013), FIGO stage IV disease (p < 0.001) and larger residual disease volume (p = 0.001) were significantly associated with shorter overall survival (OS) in univariate analysis. In Cox multivariate analysis, only FIGO stage (p = 0.001) and residual disease volume (p = 0.003) were indepen-dent prognosticators of OS. L1CAM expression in effusions was unrelated to progression-free survival (PFS). There was no association between L1CAM expression in surgical specimens and survival.Conclusion. L1CAM is overexpressed in HGSC effusions compared to surgical specimens. Its overexpression in effusions is significantly associated with shorter OS, but not independently of established prognostic factors such as FIGO stage and residual disease volume.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:76 / 81
页数:6
相关论文
共 50 条
  • [1] High-grade serous carcinoma of tubo-ovarian origin: recent developments
    Singh, Naveena
    McCluggage, W. Glenn
    Gilks, C. Blake
    HISTOPATHOLOGY, 2017, 71 (03) : 339 - 356
  • [2] Morphological patterns of high-grade serous tubo-ovarian carcinoma in association with HRD
    Aquino Correa, M. E.
    Valdivieso, L.
    Castillo, A.
    Jimeno, M.
    Hernandez, L.
    Garcia-Gomez, J.
    Matute-Molina, K.
    Feu, A.
    VIRCHOWS ARCHIV, 2024, 485 : S82 - S83
  • [3] Integrated Molecular and Clinicopathologic Study of Tubo-Ovarian High-Grade Serous Carcinoma
    Santandrea, Giacomo
    Ceccarelli, Claudio
    Santini, Donatella
    Turchetti, Daniela
    Zamagni, Claudio
    Perrone, Anna Myriam
    De Iaco, Pierandrea
    De Leo, Antonio
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 744 - 744
  • [4] High-grade serous tubo-ovarian carcinoma presenting as paraneoplastic cerebellar degeneration
    Butt, E.
    Chadda, K. R.
    Tadross, J. A.
    Latimer, J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 95 - 95
  • [5] Integrated Molecular and Clinicopathologic Study of Tubo-Ovarian High-Grade Serous Carcinoma
    Santandrea, Giacomo
    Ceccarelli, Claudio
    Santini, Donatella
    Turchetti, Daniela
    Zamagni, Claudio
    Perrone, Anna Myriam
    De Iaco, Pierandrea
    De Leo, Antonio
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 744 - 744
  • [6] LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma
    Kolb, Svenja
    Hoffmann, Inga
    Monje, Nanna
    Dragomir, Mihnea P.
    Jank, Paul
    Bischoff, Philip
    Keunecke, Carlotta
    Pohl, Jonathan
    Kunze, Catarina Alisa
    Marchenko, Sofya
    Schmitt, Wolfgang D.
    Kulbe, Hagen
    Sers, Christine
    Sehouli, Jalid
    Braicu, Elena Ioana
    Denkert, Carsten
    Darb-Esfahani, Silvia
    Horst, David
    Sinn, Bruno V.
    Taube, Eliane T.
    HUMAN PATHOLOGY, 2023, 141 : 158 - 168
  • [7] Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the COEUR cohort
    Le Page, Cecile
    Rahimi, Kurosh
    Mes-Masson, Anne-Marie
    Kobel, Martin
    HISTOPATHOLOGY, 2019, 74 (04) : 663 - 666
  • [8] Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma
    Nikas, Ilias P.
    Park, Soo-Young
    Song, Min Ji
    Lee, Cheol
    Ryu, Han Suk
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (02) : 69 - 75
  • [9] Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
    Zwimpfer, T. A.
    Pandey, A.
    Fereday, S.
    Coelho, R. J. B-N.
    Twomey, L.
    Ariyaratne, D.
    Traficante, N.
    Jacob, F.
    Eller, R.
    Heinzelmann-Schwarz, V.
    Christie, E. L.
    Kennedy, C.
    Au-Yeung, G.
    Ramus, S.
    Koebel, M.
    Nelson, B.
    Goode, E. L.
    DeFazio, A.
    Bowtell, D. D. L.
    Garsed, D. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S571 - S571
  • [10] Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation
    Talhouk, Aline
    Chiu, Derek S.
    Meunier, Liliane
    Rahimi, Kurosh
    Le Page, Cecile
    Bernard, Monique
    Provencher, Diane
    Huntsman, David G.
    Masson, Anne Marie Mes
    Kobel, Martin
    SCIENTIFIC REPORTS, 2025, 15 (01):